Hormonal
Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.
High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.
metabolic endotoxaemia, in which high- fat diet and weight gain have been associated with a higher gut permeability and subsequent systemic (mild) elevation in circulating plasma LPS. This causes a state of low- grade inflammation, which is a pathological feature of a range of chronic conditions including T2D, NAFLD, chronic kidney disease and atherosclerosis.
Why this rating
Well-established in the literature reviewed, with interventional studies cited.
Source
Gut microbiome and health: mechanistic insights
Willem M. de Vos et al. · Gut · 2022
DOI 10.1136/gutjnl-2021-326789
More from this paper
- Dietary fiber fermentation by gut microbiota produces short-chain fatty acids (SCFAs) which stimulate the secretion of gut peptides (GLP-1, PYY) via GPR41/GPR43 receptors, thereby improving glucose regulation and reducing energy intake.Good
- Butyrate maintains anaerobic conditions in the colon by activating PPARγ and repressing inducible nitric oxide synthase (iNOS), which prevents the proliferation of pathogenic facultative anaerobes like Enterobacteriaceae.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →